Literature DB >> 35044649

Optical Imaging of Matrix Metalloproteinases Activity in Prostate Tumors in Mice.

Susy Kim1, Gagan Deep2,3.   

Abstract

The molecular characterization of cancer could have significant clinical benefits, including early diagnosis, making treatment decisions, and monitoring therapeutic response. In this regard, noninvasive assessment of expression/activity of specific molecules in tumors could be vital in managing cancer. Optical probes have demonstrated promise in the molecular imaging of cancer. Here, we have described a method to noninvasively assess the activity of matrix metalloproteinases (MMPs) in human prostate tumors in mice. We used an activatable probe MMPSense™ 750 FAST (MMPSense750) with fluorescent properties in the near-infrared (NIR) range with peak excitation at ~749 nm and peak emission ~775 nm. These optical properties offer the advantage of a higher depth of detection. This probe has shown immense potential in imaging MMPs activity in deeper tissue with high target-specific signal and low background autofluorescence. Therefore, this probe could be valuable in assessing MMPs activity in primary tumors and metastasis.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarker; Cancer; Matrix metalloproteinases; Optical imaging

Mesh:

Substances:

Year:  2022        PMID: 35044649     DOI: 10.1007/978-1-0716-1896-7_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  13 in total

Review 1.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 2.  Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.

Authors:  Chrisostomi Gialeli; Achilleas D Theocharis; Nikos K Karamanos
Journal:  FEBS J       Date:  2010-11-19       Impact factor: 5.542

Review 3.  Matrix Metalloproteinases' Role in Tumor Microenvironment.

Authors:  Georgina Gonzalez-Avila; Bettina Sommer; A Armando García-Hernández; Carlos Ramos
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

5.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.

Authors:  Janine T Erler; Kevin L Bennewith; Thomas R Cox; Georgina Lang; Demelza Bird; Albert Koong; Quynh-Thu Le; Amato J Giaccia
Journal:  Cancer Cell       Date:  2009-01-06       Impact factor: 31.743

6.  Exosomes secreted by prostate cancer cells under hypoxia promote matrix metalloproteinases activity at pre-metastatic niches.

Authors:  Gagan Deep; Anil Jain; Ashish Kumar; Chapla Agarwal; Susy Kim; W Matthew Leevy; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2020-01-14       Impact factor: 4.784

Review 7.  The metastatic niche: adapting the foreign soil.

Authors:  Bethan Psaila; David Lyden
Journal:  Nat Rev Cancer       Date:  2009-04       Impact factor: 60.716

8.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Authors:  Rosandra N Kaplan; Rebecca D Riba; Stergios Zacharoulis; Anna H Bramley; Loïc Vincent; Carla Costa; Daniel D MacDonald; David K Jin; Koji Shido; Scott A Kerns; Zhenping Zhu; Daniel Hicklin; Yan Wu; Jeffrey L Port; Nasser Altorki; Elisa R Port; Davide Ruggero; Sergey V Shmelkov; Kristian K Jensen; Shahin Rafii; David Lyden
Journal:  Nature       Date:  2005-12-08       Impact factor: 49.962

9.  Infrared optical imaging of matrix metalloproteinases (MMPs) up regulation following ischemia reperfusion is ameliorated by hypothermia.

Authors:  Philip A Barber; David Rushforth; Smriti Agrawal; Ursula I Tuor
Journal:  BMC Neurosci       Date:  2012-06-28       Impact factor: 3.288

Review 10.  Role of Matrix Metalloproteinases in Angiogenesis and Cancer.

Authors:  Saray Quintero-Fabián; Rodrigo Arreola; Enrique Becerril-Villanueva; Julio César Torres-Romero; Victor Arana-Argáez; Julio Lara-Riegos; Mario Alberto Ramírez-Camacho; María Elizbeth Alvarez-Sánchez
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.